<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="Activity\PMC7738283\results\search\disease\results.xml">
  <result pre="specific demethylase 1 (LSD1) has been an epigenetic target for" exact="cancer" post="therapy since its identification in 20041. Aberrant over-expression of"/>
  <result pre="inhibitors also effectively reduce the tumour growth against different human" exact="cancer" post="cells7,8. Figure 1. Chemical structures of LSD1 inhibitors. Chalcones"/>
  <result pre="and natural chalcones exhibited the potent anticancer activity against many" exact="cancer" post="cell lines12,13. Chalcone 1 (Figure 2), a natural product"/>
  <result pre="of ABCG2 and reverse ABCG2-mediated multidrug resistance in human multidrug-resistant" exact="cancer" post="cell lines14. Chalcone 2 exhibited the reduction of tumour"/>
  <result pre="cell line16. Chalcone 4 displayed the potent antiproliferative activity against" exact="cancer" post="cells by up-regulating the expression of P53 protein17. Figure"/>
  <result pre="to the published references [21,22]. After the incubation for 24â€‰h," exact="cancer" post="cell lines were cultured with the chalcone D6 at"/>
  <result pre="of preliminary SAR. Antiproliferative effects of chalcone D6 against different" exact="cancer" post="cell lines Based on the screening activity results of"/>
  <result pre="experiments for evaluating its antiproliferative potential. In addition, Hela (cervical" exact="cancer" post="cells), 22RV1 (prostate cancer cells), Caco-2 (colon cancer cells),"/>
  <result pre="antiproliferative potential. In addition, Hela (cervical cancer cells), 22RV1 (prostate" exact="cancer" post="cells), Caco-2 (colon cancer cells), BEL-7402 (liver cancer cells),"/>
  <result pre="Hela (cervical cancer cells), 22RV1 (prostate cancer cells), Caco-2 (colon" exact="cancer" post="cells), BEL-7402 (liver cancer cells), MOLT-4 (leukaemia cells), OVCAR-3"/>
  <result pre="22RV1 (prostate cancer cells), Caco-2 (colon cancer cells), BEL-7402 (liver" exact="cancer" post="cells), MOLT-4 (leukaemia cells), OVCAR-3 (ovarian cancer cells), HCT-8"/>
  <result pre="cells), BEL-7402 (liver cancer cells), MOLT-4 (leukaemia cells), OVCAR-3 (ovarian" exact="cancer" post="cells), HCT-8 (cecal adenocarcinoma cells) and IMR-32 (neuroblastoma cells)"/>
  <result pre="antitumor agent. Figure 4. Cell viability of D6 against different" exact="cancer" post="cell lines for 48â€‰h and 72â€‰h. *Pâ€‰ Pâ€‰ Pâ€‰"/>
  <result pre="KawaharaM, TatsumiG, et al.A novel LSD1 inhibitor NCD38 ameliorates MDS-related" exact="leukemia" post="with complex karyotype by attenuating leukemia programs via activating"/>
  <result pre="inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating" exact="leukemia" post="programs via activating super-enhancers. Leukemia2017;31:2303â€&quot;14.28210006 2TatsumiG, KawaharaM, YamamotoR, et"/>
  <result pre="Oncol2016;9:24.26970896 5PrzespolewskiA, WangES.Inhibitors of LSD1 as a potential therapy for" exact="acute myeloid leukemia." post="Expert Opin Investig Drugs2016;25:771â€&quot;80. 6MouldDP, McGonagleAE, WisemanDH, et al.Reversible"/>
  <result pre="5PrzespolewskiA, WangES.Inhibitors of LSD1 as a potential therapy for acute" exact="myeloid leukemia." post="Expert Opin Investig Drugs2016;25:771â€&quot;80. 6MouldDP, McGonagleAE, WisemanDH, et al.Reversible"/>
  <result pre="based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric" exact="cancer" post="cell growth, invasion, and migration. J Med Chem2013;56:8543â€&quot;60.24131029 8SharmaSK,"/>
  <result pre="et al.Prediction of chalcone derivative cytotoxicity activity against MCF-7 human" exact="breast cancer" post="cell by Monte Carlo method. J Mol Struct2019;1181:305â€&quot;11. 10RiazS,"/>
  <result pre="al.Prediction of chalcone derivative cytotoxicity activity against MCF-7 human breast" exact="cancer" post="cell by Monte Carlo method. J Mol Struct2019;1181:305â€&quot;11. 10RiazS,"/>
  <result pre="of chalcones acting against topoisomerase IIÎ± and their cytotoxicity towards" exact="cancer" post="cell lines. J Enzyme Inhib Med Chem2019;34:134â€&quot;43.30394113 13LamiePF, PhiloppesJ.N"/>
  <result pre="14WuCP, LusvarghiS, HsiaoSH, et al.Licochalcone A selectively resensitizes ABCG2-overexpressing multidrug-resistant" exact="cancer" post="cells to chemotherapeutic drugs. J Nat Prod2020;83:1461â€&quot;72.32347726 15QuaglioD, ZhdanovskayaN,"/>
  <result pre="chalcone-mimetic derivatives as notch inhibitors in a model of T-cell" exact="acute lymphoblastic leukemia." post="ACS Med Chem Lett2019;10:639â€&quot;43.30996810 16WangG, LiuW, GongZ, et al.Synthesis,"/>
  <result pre="derivatives as notch inhibitors in a model of T-cell acute" exact="lymphoblastic leukemia." post="ACS Med Chem Lett2019;10:639â€&quot;43.30996810 16WangG, LiuW, GongZ, et al.Synthesis,"/>
  <result pre="of new naphthalene-chalcone derivatives as potential anticancer agents on MCF-7" exact="breast cancer" post="cells by targeting tubulin colchicine binding site. J Enzyme"/>
  <result pre="new naphthalene-chalcone derivatives as potential anticancer agents on MCF-7 breast" exact="cancer" post="cells by targeting tubulin colchicine binding site. J Enzyme"/>
  <result pre="al.Antiproliferative activity and p53 upregulation effects of chalcones on human" exact="breast cancer" post="cells. J Enzyme Inhib Med Chem2019;34:1093â€&quot;9.31117836 18Viegas-JuniorC, DanuelloA, daS,"/>
  <result pre="activity and p53 upregulation effects of chalcones on human breast" exact="cancer" post="cells. J Enzyme Inhib Med Chem2019;34:1093â€&quot;9.31117836 18Viegas-JuniorC, DanuelloA, daS,"/>
  <result pre="al.Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human" exact="leukemia" post="cells and effects on clonogenic potential of murine promyelocytic"/>
 </snippets>
</snippetsTree>
